CA2917767C - Cystobactamides - Google Patents

Cystobactamides Download PDF

Info

Publication number
CA2917767C
CA2917767C CA2917767A CA2917767A CA2917767C CA 2917767 C CA2917767 C CA 2917767C CA 2917767 A CA2917767 A CA 2917767A CA 2917767 A CA2917767 A CA 2917767A CA 2917767 C CA2917767 C CA 2917767C
Authority
CA
Canada
Prior art keywords
group
cystobactamide
alkyl
formula
ome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2917767A
Other languages
English (en)
French (fr)
Other versions
CA2917767A1 (en
Inventor
Sascha Baumann
Jennifer HERRMANN
Kathrin MOHR
Heinrich Steinmetz
Klaus Gerth
Ritesh RAJU
Rolf Muller
Mostafa Hamed
Liang Liang Wang
Rolf Hartmann
Walid A. M. Elgaher
Andreas Kirschning
Maria Moreno
Franziska Gille
Stephan HUETTEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Zentrum fuer Infektionsforschung HZI GmbH
Original Assignee
Helmholtz Zentrum fuer Infektionsforschung HZI GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum fuer Infektionsforschung HZI GmbH filed Critical Helmholtz Zentrum fuer Infektionsforschung HZI GmbH
Publication of CA2917767A1 publication Critical patent/CA2917767A1/en
Application granted granted Critical
Publication of CA2917767C publication Critical patent/CA2917767C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/44Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having carbon atoms of carboxamide groups, amino groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00Preparation of nitrogen-containing organic compounds
    • C12P13/02Amides, e.g. chloramphenicol or polyamides; Imides or polyimides; Urethanes, i.e. compounds comprising N-C=O structural element or polyurethanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2917767A 2013-07-12 2014-07-14 Cystobactamides Active CA2917767C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13003539.7 2013-07-12
EP13003539 2013-07-12
PCT/EP2014/001925 WO2015003816A2 (en) 2013-07-12 2014-07-14 Cystobactamides

Publications (2)

Publication Number Publication Date
CA2917767A1 CA2917767A1 (en) 2015-01-15
CA2917767C true CA2917767C (en) 2022-05-03

Family

ID=48792948

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2917767A Active CA2917767C (en) 2013-07-12 2014-07-14 Cystobactamides

Country Status (7)

Country Link
US (3) US20160145304A1 (enExample)
EP (1) EP3019615B1 (enExample)
JP (1) JP6730183B2 (enExample)
CN (1) CN105793424B (enExample)
AU (1) AU2014289663B2 (enExample)
CA (1) CA2917767C (enExample)
WO (1) WO2015003816A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160145304A1 (en) 2013-07-12 2016-05-26 Helmholtz-Zentrum für Infektionsforschung GmbH Cystobactamides
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
KR101747702B1 (ko) * 2014-05-15 2017-06-19 한국생명공학연구원 신규한 항균성 화합물 및 이의 용도
US10519099B2 (en) 2014-11-26 2019-12-31 Helmholtz-Zentrum für Infektionsforschung GmbH Cystobactamides
CN105712894A (zh) * 2016-03-23 2016-06-29 叶芳 一种3-甲氧基-4-氨基苯甲酸及其制备方法
JP7037122B2 (ja) * 2016-09-28 2022-03-16 日産化学株式会社 ジアミンおよびその利用
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CA3069720A1 (en) 2017-07-11 2019-01-17 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
CN110997641A (zh) * 2017-07-18 2020-04-10 柏林工业大学 新的白纹黄单胞菌毒素衍生物、其用途及合成
AU2018321152B2 (en) * 2017-08-23 2023-07-06 Helmholtz-Zentrum für Infektionsforschung GmbH Novel cystobactamide derivatives
SG11202001684PA (en) 2017-10-06 2020-03-30 Forma Therapeutics Inc Inhibiting ubiquitin specific peptidase 30
CA3087261A1 (en) 2018-01-10 2019-07-18 Recurium Ip Holdings, Llc Benzamide compounds
KR102708681B1 (ko) 2018-02-13 2024-09-26 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
EP4600247A3 (en) 2018-04-19 2025-11-19 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
ES2988920T3 (es) 2018-05-17 2024-11-22 Forma Therapeutics Inc Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina
UA126421C2 (uk) 2018-07-13 2022-09-28 Гіліад Сайєнсіз, Інк. Інгібітори pd-1/pd-l1
PL3860989T3 (pl) 2018-10-05 2023-07-10 Forma Therapeutics, Inc. Sprzężone piroliny, które działają jako inhibitory proteazy 30 swoistej dla ubikwityny (usp30)
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
JP2022539208A (ja) 2019-07-03 2022-09-07 スミトモ ファーマ オンコロジー, インコーポレイテッド チロシンキナーゼ非受容体1(tnk1)阻害剤およびその使用
MX2022006865A (es) 2019-12-06 2022-07-11 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio.
WO2022212080A1 (en) * 2021-03-31 2022-10-06 Medibeacon Inc. Purification of substituted diaminopyrazine dicarboxylic acids
CN117794920A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂
CN113563220B (zh) * 2021-06-25 2023-08-29 华中农业大学 一种抗菌化合物及其应用
CN121712741A (zh) 2023-06-26 2026-03-20 亥姆霍兹感染研究中心有限公司 新型囊菌酰胺衍生物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525354A (en) * 1983-09-14 1985-06-25 University Of Hawaii Antibiotic and process for the production thereof
US7020622B1 (en) * 1997-06-10 2006-03-28 Linkshare Corporation Transaction tracking, managing, assessment, and auditing data processing system and network
FR2772025B1 (fr) 1997-12-10 2000-03-03 Guerbet Sa Chelates metalliques de macrocycles polyaminocarboxyliques et leur application a l'imagerie par resonance magnetique
DE60114865T2 (de) * 2000-04-28 2006-07-27 Kosan Biosciences, Inc., Hayward Heterologe herstellung von polyketiden
IL153688A0 (en) * 2000-06-28 2003-07-06 Teva Pharma Carvedilol
AU2003286498A1 (en) * 2002-10-18 2004-05-04 Centre De Cooperation Internationale En Recherche Agronomique Pour Le Developpement (Cirad) Complete biosynthetic gene set for biosynthesis of albicidin, resistance genes, and uses thereof
JPWO2006109846A1 (ja) 2005-04-06 2008-11-20 武田薬品工業株式会社 トリアゾール誘導体およびその用途
US7758972B2 (en) * 2006-09-26 2010-07-20 Semiconductor Energy Laboratory Co., Ltd. Stilbene derivative, light emitting element, light emitting device, and electronic appliance
JP5379965B2 (ja) * 2006-09-26 2013-12-25 株式会社半導体エネルギー研究所 スチルベン誘導体、発光素子および発光装置
US8618324B2 (en) * 2007-03-13 2013-12-31 Board Of Regents, The University Of Texas System Composition and method for making oligo-benzamide compounds
US8236983B2 (en) * 2008-03-13 2012-08-07 Board Of Regents, The University Of Texas System Composition and method for the treatment of diseases affected by apoptosis
WO2013078277A1 (en) * 2011-11-23 2013-05-30 The Board Of Regents Of The University Of Texas System Oligo-benzamide compounds and their use in treating cancers
JP6474736B2 (ja) * 2013-02-15 2019-02-27 テヒーニィシエ ウニヴェルジテート ベルリン アルビシジン誘導体、その使用および合成
US20160145304A1 (en) * 2013-07-12 2016-05-26 Helmholtz-Zentrum für Infektionsforschung GmbH Cystobactamides
KR101747702B1 (ko) 2014-05-15 2017-06-19 한국생명공학연구원 신규한 항균성 화합물 및 이의 용도
US10519099B2 (en) * 2014-11-26 2019-12-31 Helmholtz-Zentrum für Infektionsforschung GmbH Cystobactamides

Also Published As

Publication number Publication date
CN105793424B (zh) 2021-02-19
JP6730183B2 (ja) 2020-07-29
US11225503B2 (en) 2022-01-18
CA2917767A1 (en) 2015-01-15
US20200331964A1 (en) 2020-10-22
EP3019615B1 (en) 2021-04-07
CN105793424A (zh) 2016-07-20
WO2015003816A2 (en) 2015-01-15
US10793600B2 (en) 2020-10-06
AU2014289663A1 (en) 2016-02-04
US20190185514A1 (en) 2019-06-20
AU2014289663B2 (en) 2019-03-07
US20160145304A1 (en) 2016-05-26
WO2015003816A3 (en) 2015-03-12
JP2016527215A (ja) 2016-09-08
EP3019615A2 (en) 2016-05-18

Similar Documents

Publication Publication Date Title
US11225503B2 (en) Crystobactamides
Degrassi et al. Plant growth-promoting Pseudomonas putida WCS358 produces and secretes four cyclic dipeptides: cross-talk with quorum sensing bacterial sensors
KR100379100B1 (ko) 스트렙토그라민및돌연변이합성에의한이의제조방법
CA2466340C (en) Farnesyl dibenzodiazepinone, processes for its production and its use as a pharmaceutical
CN107001241B (zh) 新型孢囊菌酰胺
CA2695813A1 (en) Thiopeptide precursor protein, gene encoding it and uses thereof
AU2005265443A1 (en) DNA coding for polypeptide participating in biosynthesis of pladienolide
Gromyko et al. Generation of Streptomyces globisporus SMY622 strain with increased landomycin E production and it's initial characterization
EP3309253B1 (en) Genes for biosynthesis of tetracycline compounds and uses thereof
HK1229840B (en) Cystobactamides
DK2509950T3 (en) 5-amino-4-hydroxypentoylamides
KR100814098B1 (ko) 히스톤 디아세틸라제 저해활성을 갖는 알킬아미노나프탈렌일옥시 메틸옥트 n-하이드록시엔아마이드 유도체,이의 제조방법 및 이를 유효성분으로 하는 항암제용 약학조성물
KR100532356B1 (ko) 스트렙토마이세스 속 균주로부터 유래된 카르바모일 트랜스퍼레이즈의 아미노산서열 및 이를 코딩하는 유전자의 염기서열
CN117642417A (zh) 新型达罗巴汀衍生物
CA2538147A1 (en) Farnesyl dibenzodiazepinone, processes for its production and its use as a pharmaceutical
WO2006045063A2 (en) Heterologous genes for encoding polyketides
KR19990074514A (ko) 아미노글라이코사이드계 항생제에 대해 다제내성을지정하는유전자

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190219

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250703

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250703